Rain Therapeutics
Developing small molecule targeted therapeutics for cancer patients that possess a clear, and single, oncogenic driver. Learn more
Launch date
Employees
Market cap
€40.0m
Enterprise valuation
(€30m) (Public information from Jan 2024)
Share price
$1.21 RAIN
Fremont California (HQ)
Authorizing premium user...